The use and effectiveness of temozolomide in children with central nervous system tumours: a survey from the Canadian Paediatric Brain Tumour Consortium.

摘要: Objective To describe the use of temozolomide (TMZ) in Canadian children treated for brain tumours and to evaluate survival predictors with this agent. Methods A survey was conducted within Paediatric Brain Tumour Consortium (CPBTC), a group tertiary care centres pediatric neurooncology ( n = 16) Canada that are involved treatment central nervous system tumours. Results In 10 16 participating oncology CPBTC, 137 were TMZ between January 2000 March 2006. Although 33% enrolled into clinical trial, 67% outside open studies. Most patients (72%) received on recurrence their tumour (first or subsequent). The most commonly administered regimen single-agent 150-200 mg/ m2 5 consecutive days every 28 days. median duration 141 (range: 4 1102 days). Response data provided 127 patients, whom 6 showed complete response. Sixteen experienced minor partial response, 53 had stable disease, 52 progressive disease. Of 32 alive at last follow-up, 19 diagnosis low-grade glioma. Conclusions Temozolomide is used variety tumours, often time recurrence. lack insight clear indications agent tumours-used either alone combination therapy-may be result suboptimal design phase I II studies III trials population.